To our knowledge, this study is the first report on adverse drug reactions and safety profile of TAS-102 for metastatic colorectal cancer in clinical practice. Serious neutropenia and febrile neutropenia (FN) tended to occur from days 15 to 21 in the first cycle. Careful monitoring of patients with serious neutropenia around day 15 in the first cycle should be done to prevent FN. Background: Unexpected toxicities of newly approved drugs might be revealed in clinical practice after market launch. This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch. Patients and Methods: All metastatic colorectal cancer (mCRC) patients (pts) received TAS-102 35 mg/m 2 as a starting dose orally twice daily for 5 consecutive days, with 2 days of rest per week for 2 weeks, followed by a 14-day rest period. ADRs during treatment courses were reported spontaneously by attending physicians. Results: From May 26 to November 25, 2014, 3420 mCRC pts were treated with TAS-102 at 1134 institutes in Japan. In total, 370 ADRs (185 ADRs of myelosuppression and related infection in 125 pts, of which 58 ADRs in 31 pts were serious ADRs [SADRs] and 127 ADRs in 98 pts were non-SADRs) were observed in 219 pts and included 89 SADRs in 51 pts and 281 non-SADRs in 183 pts (a pt was counted twice if SADR and non-SADR were experienced). The most frequent ADRs were: myelosuppression comprising neutropenia (n ¼ 77), leukopenia (n ¼ 28), thrombocytopenia (n ¼ 23), anemia (n ¼ 20), and febrile neutropenia (FN; n ¼ 19). Serious neutropenia and FN tended to occur from days 15 to 21 in the first cycle in 12 (75%) of 16 pts. Conclusion: The ADRs and safety profile of TAS-102 in this study was similar to that in recent TAS-102 clinical trials, without unexpected safety signals. Careful monitoring should be undertaken in pts with serious neutropenia around day 15 in the first cycle of treatment to prevent FN. Clinical Colorectal Cancer, Vol. 15, No. 4, e205-11 ª 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Colorectal cancer is the fourth leading cause of cancer death worldwide and the third in Japan. 1, 2 Systemic chemotherapy for metastatic colorectal cancer (mCRC) has advanced in the past several decades. Active agents and combination therapy with cytotoxic agents, including fluoropyrimidines (fluorouracil/folic acid, capecitabine and tegafur/gimeracil/oteracil potassium [S-1]), oxaliplatin, and irinotecan in combination with biological agents such as bevacizumab and ziv-aflibercept (anti-vascular endothelial growth factor monoclonal antibodies), ramucirumab (anti-vascular endothelial growth factor receptor monoclonal antibody), cetuximab and panitumumab (anti-epidermal growth factor receptor monoclonal antibodies), and regorafenib (oral multikinase inhibitor) are the key strategy for mCRC treatment. [3] [4] [5] However, there remains an unmet medical need in clinical practice for the treatment of mCRC, particularly in patients who are maintaining good physical conditions but are refractory or intolerant to all standard therapies.
TAS-102 (Taiho Pharmaceutical Co, Ltd, Tokyo, Japan) is a novel oral antitumor agent composed of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil hydrochloride, at a molar ratio of 1:0.5 (weight ratio, 1:0.471). On the basis of results of a randomized phase II trial, 6 TAS-102 was approved for the first time in March 2014 in Japan by the Pharmaceutical and Medical Devices Agency (PMDA), with an initial indication being in patients with mCRC only who are refractory to all standard therapies defined in the Japanese colorectal cancer treatment guideline, 3 and under a conditional approval that required a phase III trial of TAS-102 (RECOURSE trial), a large-scale global phase III trial to evaluate the efficacy and safety of TAS-102 versus placebo in patients with mCRC refractory to all standard chemotherapies. The RECOURSE trial showed a significant improvement in overall survival and progression-free survival in favor of TAS-102 over placebo, with a hazard ratio of 0.68 and 0.48, respectively (both P < .0001). 7 Accordingly, the indication of TAS-102 was revised to treatment for patients with mCRC after submission of the positive results of the RECOURSE trial to the Japanese health authorities in March 2015.
The safety review of TAS-102 in the randomized phase II and RECOURSE trial revealed myelosuppression and related infection as identified risks, and ileus, cardiac disorders, and interstitial lung disease (ILD) as potential risks. Unexpected serious adverse drug reactions (SADRs) not identified in clinical trials might emerge because of the rapid increase in the number of patients in real-world clinical practice as well as its patient diversity from those in clinical trials, because many patients with mCRC are elderly (median age at diagnosis, approximately 70 years). 8 In addition, adverse drug reactions (ADRs) are an important consideration when making treatment decisions. Therefore, it is essential to detect emerging issues of a new drug as signals, as early as possible in the postmarketing setting, and to analyze and detect risks to assure the safety of these medical products.
The Pharmaceuticals and Medical Devices Agency in Japan requires marketing authorization holders (MAH) to conduct early postmarketing phase vigilance as a pharmacovigilance strategy of the risk management plan for new drugs approved in Japan since 2014. MAH undertake safety assurance activities within the first 6 months after market launch of the drug to collect information of ADRs from a wide patient population to promote proper use of a new drug in clinical practice and to assure early detection of SADRs. 9 The aim of this postmarketing surveillance study was to investigate the expected and unexpected ADRs of TAS-102 in real-world clinical practice, compared with those reported from previously observed data of clinical trials, to facilitate the proper use of TAS-102 in clinical practice.
Patients and Methods
The postmarketing surveillance study of TAS-102 was conducted to collect accurate information of ADRs in patients with mCRC treated with TAS-102 from May 26 to November 25, 2014.
Eligible patients were mCRC patients refractory to all standard chemotherapies, who provided informed consent before treatment, were not receiving combination treatment with other cytotoxic or biological agents, with no history of serious hypersensitivity reactions to any components of TAS-102, and were not pregnant or lactating. This study was conducted in accordance with Good Vigilance Practice (GVP) of the Ministry of Health, Labour, and Welfare, Japan. Approval by the ethics committee of each institution was not mandatory, because GVP does not require such approval for a postmarketing surveillance study.
This was a postmarketing surveillance study, in which the ADR collection is dependent upon spontaneous reporting. The number of TAS-102 prescriptions and patients treated with TAS-102 during the study period are only estimates on the basis of a preregistration system, in which registration forms were faxed to the Patient Registration Center from the institute before TAS-102 was administered. Because the preregistration by fax was not mandatory, the precise number of patients could not be determined. However, the company strongly recommended, from the proper use standpoint, that all physicians register patients by fax. The number of registrations by fax supported the estimated number of patients who were prescribed TAS-102 in daily practice.
A treatment cycle included 35 mg/m 2 of TAS-102 as a starting dose administered orally twice daily 1 hour after breakfast and dinner, for 5 consecutive days, with 2 days of rest per week for 2 weeks, followed by a 14-day rest period. To assure proper use of TAS-102 and patient safety, a "Guidance on the proper usage of TAS-102" document was distributed to health care professionals. This included guidance regarding facility requirements, patient criteria for starting treatment, periodic laboratory tests, prophylaxis and early detection of adverse reactions, coordination with a specialist for respective adverse reactions, and informed consent. Facility requirements included the presence of expert physicians, and availability of emergency treatments. Cooperation for all-case preregistration criteria for starting TAS-102 treatment were: Eastern Cooperative Oncology Group performance status (PS) of 0 or 1, absolute neutrophil count of 1500/mm 3 , platelet count 75,000/mm 3 , hemoglobin 8.0 g/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 100 IU/L (for patients with liver metastases, AST and ALT 200 IU/L), total bilirubin 1.5 mg/dL, serum creatinine 1.5 mg/dL, no evidence of active infection, peripheral neuropathy Grade 2, and other nonhematological toxicities Grade 1 (excluding alopecia, dysgeusia, pigmentation, and symptoms associated with the primary cancer), according to Common Terminology Criteria for Adverse Events version 3.0. These criteria were determined on the basis of the protocol of the randomized phase II trial for TAS-102. 6 Adverse drug reactions were defined as events for which a causal relationship with TAS-102 could not be ruled out or was unknown. SADR was defined as any event that resulted in death, was incapacitating, required inpatient hospitalization or prolongation of existing hospitalization for treatment, was equivalent in seriousness to any of the aforementioned events, or resulted in a congenital anomaly/birth defect according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E2D 10 and E2A 11 guidelines. A patient was counted twice if experiencing SADR(s) and non-SADR(s).
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Results of TAS-102 Postmarketing Surveillance Study
To ensure appropriate use of TAS-102 and early detection of ADRs, all patients were required to undergo examinations of their physical and nonphysical conditions on the day before starting treatment, and on days 15 and 22 of the first treatment cycle. Thereafter, patients were to undergo examination on the day before starting treatment and on day 15 of each treatment cycle (see Supplemental Tables 1 and 2 in the online version).
Role of the Funding Source
The sponsor contributed to study design, data collection, and data interpretation. The corresponding author had full access to all of the data in the study and has the responsibility of the final decision to submit for publication.
Results
The number and characteristics of patients were obtained from the data provided in the preregistration fax during enrollment. During the 6-month period, 3420 patients (male, 2065 patients; 60.4%) from 1134 institutes were registered. Median age of the patients was 66 (range, 24-92) years; 2149 patients were younger than 70 years, and 1270 patients were 70 years or older (1 patient, age unknown). Median body mass index was 21.9 (range, 12.5-42.7) kg/m 2 . Most patients had PS 0 or 1 (99.3%; 3396 patients), followed by PS 2 (0.6%; 21 patients), and PS 3 (0.1%; 3 patients) ( Table 1) .
On the basis of spontaneous reports by attending physicians, a total of 370 ADRs were observed in 219 patients and included 89 SADRs in 51 patients and 281 non-SADRs in 183 patients. A significant increase in either SADR or non-SADR in patients 70 years or older was not apparent compared with patients younger than 70 years.
Hematological ADRs
Of 370 ADRs, a total of 185 ADRs of myelosuppression and related infections were observed in 125 patients, of which 58 ADRs in 31 patients were SADRs and 127 ADRs in 98 patients were non-SADRs.
The major ADRs of myelosuppression were neutropenia, leukopenia, thrombocytopenia, anemia, and febrile neutropenia (FN). In total, there were 167 ADRs among these major hematological ADRs, comprised of neutropenia (7 SADRs and 70 Table 2) . Further, 162 of the 167 ADRs (97%) were confirmed to have resolved or were resolving. Serious neutropenia and FN tended to occur from days 15 to 21 in the first treatment cycle in 12 (75.0%) of 16 patients (Figure 1 ). Fourteen of the 16 patients were confirmed to have recovered or were recovering; among them, 64.2% (9 patients) recovered or were recovering around day 6 after onset (median, 7 days; range, 5-20 days). A detailed investigation report was available in 11 patients, and showed that granulocyte-colony stimulating factor (G-CSF) was given to 8 patients (72.7%) and prophylactic and/or therapeutic antibiotics to 10 patients (90.9%). Treatment-related death due to infection induced by serious neutropenia was observed in 2 patients-1 experienced FN on day 15 and the other experienced it on day 18.
In 36 of the 52 patients, nonserious neutropenia tended to occur from days 22 to 28 in the first treatment cycle ( Figure 2) ; it was confirmed that all patients had recovered or were recovering with appropriate therapeutic measures. In 23 of the 52 patients (44.2%), neutropenia had resolved or was resolving at around day 7 after onset (median, 10 days; range, 2-89 days).
Nonhematological ADRs
Interstitial lung disease was observed in 7 patients, including 3 patients with a history of ILD related to previous treatment, and all patients were confirmed to have recovered or were recovering (Table 3) . Median time to onset was 51 days (range, 22-91 days), and median time to recovery was 10 days (range, 7-39 days). Twenty-five ADRs of diarrhea were observed in 25 patients, of which 5 were serious. Of the 5 patients, 4 were confirmed to have recovered, and 1 did not recover and died due to infection secondary to myelosuppression.
Forty-six ADRs, comprising 33 ADRs of nausea and 13 of vomiting, were observed in 38 patients; of these, 2 ADRs each of nausea and vomiting in 3 patients were serious. The median onset of nausea was day 6 for these 33 ADRs. All 3 patients with serious nausea/vomiting were confirmed to have recovered between days 6 and 8 after onset. Thirty-one ADRs of decreased appetite were observed in 31 patients of whom 4 were SADRs. Decreased appetite was most frequently observed to have developed on day 8 of treatment. Seventeen ADRs of fatigue/malaise were observed in 17 patients, but were nonserious. Three ADRs of cardiac disorders were observed in 2 patients; of these, 1 patient with concurrent cardiac ischemia developed decreased left ventricular function and the other, with a history of myocardial infarction and complications of hypertension, hyperlipidemia, and diabetes mellitus, experienced congestive heart failure and atrial fibrillation after receiving TAS-102. Ileus was not observed in any patients.
Discussion
To our knowledge, this postmarketing surveillance study is the first on ADRs and safety profile of TAS-102 for mCRC patients in the first 6 months after market launch from its use in real-world clinical practice worldwide since TAS-102 was first approved in Japan. There are limitations to this study because information regarding ADRs and SADRs was obtained through spontaneous reporting. Because of this, the actual number of patients enrolled in this study as well as the ADR and SADR frequencies could not be calculated. The patient characteristics obtained via fax were referred to analyze the patient characteristics in this study. In this study, serious neutropenia and FN tended to occur from days 15 to 21 in the first treatment cycle in 12 (75.0%) of the 16 patients, and resolved promptly or was resolving with the use of G-CSF or with prophylactic and/or therapeutic antibiotics. A drug rest period of 2 weeks, in accordance with a 5 days-on and 2 daysoff schedule for 2 weeks, was set as the convalescence period from hematological toxicity on the basis of results from previous phase I studies. [12] [13] [14] [15] [16] Because the nadir of hematological toxicity was most frequently observed during the 2-week rest period in this study, the setting of this rest period was supported by our results as well as those from previous clinical trials.
Serious neutropenia might result in a fatal outcome, because there were 2 patients who died because of infection resulting from serious neutropenia. The prophylactic use of G-CSF is not allowed in Japan. Therefore, G-CSF was not used prophylactically in the randomized phase II trial or the RECOURSE trial, although the proactive use of G-CSF as supportive care when observing neutropenia was allowed. The proportion patients who experienced neutropenia who received G-CSF as supportive care was reported to be 9% in the RECOURSE trial, 7 and was reported as 21.8% by Kotani et al. 17 Thus, findings from this study suggest that appropriate measures such as dose adjustment, drug discontinuation, and/ or use of G-CSF and prophylactic and/or therapeutic antibiotics need to be considered in patients with neutropenia.
Interstitial lung disease was observed in 7 patients, all of whom were confirmed to have recovered or were recovering; of these, 3 patients had a history of ILD associated with previous chemotherapy. In a phase II study conducted in Japan, ILD was noted in 1 of 113 patients (0.9%). This case of ILD was considered to be associated with a viral infection on the basis of the clinical course and lung biopsy, and causality associated with TAS-102 was ruled out. No ILD was observed in the RECOURSE trial. However, these findings suggest that careful attention is required when TAS-102 is administered in patients with a history of ILD.
Furthermore, this study showed that diarrhea might occur at any time during the first cycle of TAS-102 treatment and tends to resolve in a relatively short period of time. In case of nausea, most patients experienced the ADRs within 7 days after starting the treatment; this tendency was also observed for anorexia.
The inclusion criteria of this study were established on the basis of the "Guidance on the proper usage of TAS-102 document." In this study, 3396 of 3420 patients (99.3%) registered by fax had a PS 0 or 1. More toxicity might occur if patients with more advanced disease are involved. In their recent publication on the clinical use of TAS-102, Dr Kotani and colleagues reported no significant difference between PS 0-1 and PS 2 patients in terms of the safety profile, although their report was solely on the patients observed in their hospital. 17 Only Japanese patients were enrolled in this study. However, a geographic analysis of the RECOURSE trial, which was conducted globally, suggested no ethnic difference in terms of the safety profile. 18 In addition, in the phase I study conducted in the United States by Dr Bendell and colleagues, no safety profile difference was found between the Japanese and Caucasian populations. 19 Therefore, we believe that the results from this study can be applied to Caucasian populations. In addition, an expanded access program currently ongoing in the United States might also support the conclusion of this study (ie, there is no ethnic difference between Japanese and Caucasian populations with regard to the use of TAS-102).
Achieving a treatment period with TAS-102 for as long as possible, while minimizing toxicity risks to maintain a positive benefit:risk balance, is a key strategy for treating mCRC patients. The results from this study reflect ADR profiles of TAS-102 in realworld clinical practice. Although there are limitations to this study, recognition of the profile of ADRs over time can help health care professionals to prepare for the effect of these events on real-world mCRC patients, who are typically elderly and have already been exposed to a range of toxicities from previous lines of therapy. In addition, the most common ADRs identified in the study have been frequently observed in TAS-102 clinical trials, and awareness of this consistent toxicity profile allows health care professionals to advise patients on early identification and reporting of symptoms. The time profile of ADR occurrences in this study highlights the importance of initiating proactive monitoring of patients when initiating treatment. A number of measures have been identified that help prevent or limit the effects of ADRs. Another prospective postmarketing surveillance study of TAS-102 with a large sample size is now ongoing in Japan. This study is conducted as part of another pharmacovigilance strategy to examine factors affecting the safety and efficacy of TAS-102 treatment in clinical practice for mCRC patients. This study was designed to observe the frequency of ADRs and SADRs in patients with or without impaired renal function or liver dysfunction.
Conclusion
The ADR and safety profile of TAS-102 observed in this postmarketing surveillance study in clinical practice were similar to those from recent TAS-102 randomized clinical trials. There were no unexpected safety signals. Careful monitoring of myelosuppression should be undertaken, to prevent FN, especially in patients who develop serious neutropenia around day 15 in the first treatment cycle.
Clinical Practice Points
Newly approved drugs might have unexpected toxicities that emerge in clinical practice after market launch. To our knowledge, this large-scale surveillance study is the first to show the safety profile of TAS-102 in real-world clinical practice among patients with mCRC refractory to all standard chemotherapies. The ADR and safety profile of TAS-102 observed in this surveillance study were similar to those from recent TAS-102 randomized clinical trials. Careful monitoring of patients with serious neutropenia around day 15 in the first treatment cycle should be undertaken to prevent FN. This study was undertaken worldwide to investigate expected and unexpected ADRs of TAS-102 in real-world clinical practice, including at nonspecialized hospitals, in the first 6 months after its launch in Japan. In addition, awareness of a consistent toxicity profile allows health care professionals to advise patients regarding early identification and reporting of symptoms. The time profile of ADR occurrences in this study highlights the importance of initiating proactive monitoring of patients when initiating treatment.
